| Literature DB >> 24376805 |
Awatif M Abdulsalam1, Init Ithoi2, Hesham M Al-Mekhlafi3, Abdulsalam M Al-Mekhlafi4, Abdulhamid Ahmed5, Johari Surin2.
Abstract
BACKGROUND: Blastocystis is a genetically diverse and a common intestinal parasite of humans with a controversial pathogenic potential. This study was carried out to identify the Blastocystis subtypes and their association with demographic and socioeconomic factors among outpatients living in Sebha city, Libya. METHODS/Entities:
Mesh:
Substances:
Year: 2013 PMID: 24376805 PMCID: PMC3869855 DOI: 10.1371/journal.pone.0084372
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genbank reference sequence of Blastocystis isolates used in the construction of phylogenetic tree.
| Subtype | Accession number | Host | Reference |
|---|---|---|---|
| ST1 | AB070989 | Human | [ |
| AB107967 | Monkey | [ | |
| EU445488 | Monkey | [ | |
| ST2 | AB070997 | Monkey | [ |
| AB107969 | Monkey | [ | |
| ST3 | AM779042 | Human | [ |
| AB107963 | Pig | [ | |
| EU445494 | Human | [ | |
| ST4 | AB071000 | Rat | [ |
| AY590111 | Rat | [ | |
| ST5 | AB070998 | Pig | [ |
| AB070999 | Pig | [ | |
| ST6 | AB107972 | Bird | [ |
| AB070990 | Human | [ | |
| ST7 | AB070991 | Human | [ |
| AB107973 | Bird | [ | |
| ST8 | AB107970 | Primate | [ |
| ST9 | AF408426 | Human | [ |
Figure 1Phylogenetic tree of the SSU-rDNA gene sequences of Blastocystis isolates as inferred using the neighbour-joining method.
Isolate or strain names are as provided in Genbank as available, followed by accession numbers in parentheses. Sequences generated in this study (designated ‘LM(S), LF(S)’ followed by clones ‘a,b,c,d’) are in red font. Proteromonas lacerate (accession number U37108) served as the out-group. Bootstrap values (%) are indicated at the internal nodes (1,000 replicates). Bootstrap values of less than 50% are not shown.
Heterogeneity of Blastocystis clone against selected closest match reference from Genbank.
| Isolate (clones) from symptomatic and asymptomatic | Sequence | BI | BS | BD | No. of | ST | Reference isolate |
|---|---|---|---|---|---|---|---|
| patients | homology | BI/BS/BD | (Accession no.) | ||||
| LFS-1 (a,b,c) (other 20 isolate clones stated in | 100% | 1 | MJ99-424 (AB107967); | ||||
| LMS-5 (c,d) | 99.7% | G280 →C | 1BS | J96A-29, (AB070989) | |||
| LM-33 (c,d) | 99.7% | G280 →A | 1BS | ||||
| LM-44 (a,b), LF-45 (a,b) | 99.7% | C36→A | 1BS | ||||
| LMS-29 (a,b) | 98.9% | - 194→T | C188→ - | 1BI, 1BD | |||
| LMS-18 (a,b,c), LM-19 (a,b,c), LFS-20 (a,b,c), | 98.9% | -199→C | T208→C | T193→ - | 2BI, 1BS,2BD | ||
| LM-40 (a,b,c), LF-41 (a,b,c), LM-42 (a,d) | - 200→C | T 216→ - | |||||
| LFS-6 (a,b), LM-35 (a,c) | 98.7% | - 193→C | C188 → - | 1BI, 1BD | |||
| LM-42 (b,c) | 98.7% | -199→C | T208→C | T193→ - | 2BI, 2BS,2BD | ||
| - 200→C | C230→T | T 216→ - | |||||
| LFS-6 (c,d), LM-35 (b,d) | 98.5% | - 193→C | T209→A | C188→ - | 1BI, 1BS,1BD | ||
| LMS-16 (a,b,c), LMS-17 (a,b,c), LM-39 (a,b,c) | 99.7% | T207→C | 1BS | 2 | MJ99-116(AB107969) | ||
| LM-43 (a,b,c) | |||||||
| LM-44 (c,d), LF-45 (c,d) | 98.3% | - 198→T | T36→C | T193→ - | 2BI, 3BS,2BD | ||
|
| T208→C | T 216→ - | |||||
| A467→G | |||||||
| LMS-21 (a,b,c) (other 7 isolate clones stated in | 100% | 3 | PJ99-162(AB107963) | ||||
| LMS-29 (c,d) | 99.7% | A222→T | 1BS | ||||
| LMS-26 (a,b) | 99.1% | G214→T | 4BS | ||||
| T215→G | |||||||
| C220→A | |||||||
| T274→A |
Association between Blastocystis subtypes and related potential factors.
| Variable | ST1 | ST2 | ST3 | |||
|---|---|---|---|---|---|---|
| Frequency (%) |
| Frequency (%) |
| Frequency (%) |
| |
| Gender | 0.009 * | 0.080 | 0.431 | |||
| Female | 14 (60.9) | 3 (27.3) | 2 (25.0) | |||
| Male | 9 (39.1) | 8 (72.7) | 6 (75.0) | |||
| Age | 0.056 | 0.123 | NA | |||
| ≥18 years | 18 (78.3) | 9 (81.8) | 8 (100.0) | |||
| <18 years | 5 (21.7) | 2 (18.2) | 0 (0.00) | |||
| Education level | 0.034* | 0.008 | 0.932 | |||
| Low (≤ Primary school) | 18 (78.3) | 9 (81.8) | 5 (62.5) | |||
| High (≥Secondary school) | 5 (21.7) | 2 (18.2) | 3 (37.5) | |||
| Occupational status | 0.801 | 0.987 | 0.764 | |||
| Not working | 13 (56.5) | 6 (54.5) | 4 (50.0) | |||
| Working | 10 (43.5) | 5 (45.5) | 4 (50.0) | |||
| Family size | 0.711 | 0.974 | 0.709 | |||
| ≥ 7 members (large) | 12 (52.2) | 6 (54.5) | 5 (62.5) | |||
| < 7 members (small) | 11 (47.8) | 5 (45.5) | 3 (37.5) | |||
| Presence of animals in the house | 0.488 | 0.353 | 0.725 | |||
| Yes | 10 (43.5) | 7 (63.6) | 3 (37.5) | |||
| No | 13 (56.5) | 4 (36.4) | 5 (62.5) | |||
| Drinking water | 0.204 | 0.867 | 0.243 | |||
| Untreated | 13 (56.5) | 5 (45.5) | 4 (50.0) | |||
| Treated (chlorinated, filtered or boiled) | 10 (43.5) | 6 (54.5) | 4 (50.0) | |||
| Diarrhoea | 0.480 | 0.303 | 0.008* | |||
| Yes | 8 (34.8) | 4 (36.4) | 7 (87.5) | |||
| No | 15 (65.2) | 7 (63.6) | 1 (12.5) | |||
| Abdominal pain | 0.384 | 0.384 | 0.700 | |||
| Yes | 10 (43.5) | 6 (54.5) | 4 (50.0) | |||
| No | 13 (56.5) | 5 (45.5) | 4 (50.0) | |||
| Flatulence | 0.270 | 0.270 | 0.686 | |||
| Yes | 7 (30.4) | 5 (45.5) | 3 (37.5) | |||
| No | 16 (69.6) | 6 (54.5) | 5 (62.5) | |||
a Chi square test, bFisher’s Exact test, *Significant association (P<0.05), not applicable (NA).
Subtype distribution of human Blastocystis sp. isolates from different countries.
| Country (Ref) | Participant (no. of sample) | Subtype distribution | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ST1 | ST2 | ST3 | ST4 | ST5 | ST6 | ST7 | ST8 | ST9 | Unk/MSI | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Libya [ | Outpatient (38) | 19 | 3 | 15 | - | - | - | 1 | - | - | - |
| Australia [ | Patients (91) | 28 | 5 | 40 | 12 | - | 3 | 1 | 2 | - | - |
| Bangladesh [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Brazil [ | Indigenous community (66) | 27 | 21 | 11 | - | - | - | - | - | - | 7 |
| China [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| China [ | Rural community (78) | 16 | 1 | 55 | 1 | - | - | - | - | - | 5 |
| Denmark [ | General population (24) | 2 | 3 | 6 | 9 | - | - | - | - | 1 | 3 |
| Patients (92) | 19 | 19 | 15 | 11 | - | - | 5 | - | - | 23 | |
| Denmark [ | Patients (99) | 20 | 15 | 39 | 16 | - | 1 | - | 1 | - | 7 |
| Egypt [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Egypt [ | IBS patients (51) | 15 | - | 22 | - | - | 8 | - | - | - | 6 |
| Control (49) | - | - | 17 | - | - | 15 | 13 | - | - | 4 | |
| France [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| France [ | HM patients (15) | - | - | 3 | 10 | - | 1 | 1 | - | - | - |
| Control (12) | 1 | 1 | 1 | 7 | - | - | 2 | - | - | - | |
| Germany [ | Patient (12) | 3 | 2 | 5 | 2 | - | - | - | - | - | - |
| Greece [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Iran [ | Patient (45) | 20 | 4 | 16 | - | - | 2 | 3 | - | - | - |
| Ireland [ | Healthy persons (14) | 1 | 6 | 4 | 3 | - | - | - | - | - | - |
| Italy [ | Symptomatic (34) | 3 | 7 | 16 | 6 | - | - | 1 | 1 | - | - |
| Japan [ | Patient (50) | 4 | 0 | 26 | 2 | 0 | 11 | 5 | 0 | 2 | 0 |
| Lebanon [ |
| 10 | 5 | 3 | - | - | - | - | - | - | - |
|
| 1 | 7 | 9 | 1 | - | - | - | - | - | - | |
| Liberia [ | Schoolchildren (30) | 7 | 7 | 8 | 3 | - | - | - | - | - | 5 |
| Malaysia [ | HIV patient (20) | 3 | 1 | 11 | 5 | - | - | - | - | - | - |
| Cancer patient (20) | 2 | 1 | 9 | 6 | - | - | - | - | - | 2 | |
| Mexico [ | IBS patients (14) | 2 | 1 | 2 | - | - | - | - | - | - | 9 |
| Control (6) | - | - | 3 | - | - | - | - | - | - | 3 | |
| Nepal [ | Symptomatic (20) | 4 | 4 | 12 | - | - | - | - | - | - | - |
| Nigeria [ | Patient (23) | 10 | - | 9 | 3 | - | - | - | - | - | 1 |
| Pakistan [ | Symptomatic (10) | 2 | - | 7 | - | - | 1 | - | - | - | - |
| Pakistan [ | IBS patients (123) | 75 | 6 | 23 | 6 | 3 | 3 | 5 | - | - | 2 |
| Control (56) | 12 | 4 | 26 | 2 | 4 | 3 | 5 | - | - | - | |
| Singapore [ | Patient (9) | 2 | - | 7 | - | - | - | - | - | - | - |
| Spain [ | Symptomatic (51) | 1 | 2 | - | 48 | - | - | - | - | - | - |
| Sweden [ | Patient (63) | 10 | 9 | 30 | 13 | - | - | 1 | - | - | - |
| Thailand [ | Army personnel (153) | 138 | - | 7 | - | - | - | 2 | - | - | 6 |
| Thailand [ | Schoolchildren (68) | 53 | 15 | - | - | - | - | - | - | - | - |
| Tanzania [ | Healthy persons (6) | 1 | 3 | 2 | - | - | - | - | - | - | - |
| Turkey [ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| UK [ | Patient (54) | 3 | 9 | 22 | 17 | - | - | - | 3 | - | - |
| UK [ | IBS patients (136) | 14 | 10 | 56 | 51 | - | 1 | 1 | 3 | - | - |
| Control (135) | 20 | 16 | 58 | 34 | 2 | - | 3 | 2 | - | - | |
| USA [ | Symptomatic (9) | 1 | - | 6 | - | - | - | - | - | - | 2 |
| Total sample | 2141 | 618 | 219 | 789 | 274 | 9 | 58 | 61 | 12 | 3 | 97 |
Current study (*), mixed subtype infection (MSI), unknown (Unk), irritable bowel syndrome (IBS), hematological malignancies (HM), symptomatic (with gastrointestinal symptoms), asymptomatic (without gastrointestinal symptoms).